永生化心球来源细胞外囊泡减轻桥粒蛋白2突变小鼠致心律失常性心肌病
本研究在4周龄Dsg2mt/mt小鼠中每周给予心球来源细胞外囊泡或溶剂对照,持续4周。EV治疗改善双心室功能、减少左室扩张、缩短QRS和QTc、降低室性心律失常负荷与诱发性,并减少纤维化、细胞死亡和炎症。机制涉及hsa-miR-4488抑制NF-κB通路。
要点
- EV治疗改善Dsg2mt/mt小鼠双心室功能并减少左室扩张。
- EV降低室性心律失常负荷与诱发性,缩短QRS和QTc。
- EV减少心脏纤维化、细胞死亡和炎症,部分由hsa-miR-4488介导。
核心结论
- 细胞外囊泡治疗改善ACM小鼠心脏功能、减少心脏炎症并抑制心律失常发生。
- EV的保护作用部分通过hsa-miR-4488抑制NF-κB通路实现。
- 将本研究发现转化至人类异质性ACM前需进一步研究。
研究设计与样本
- 4周龄纯合敲入突变桥粒蛋白2(Dsg2mt/mt)小鼠随机接受每周EV或溶剂对照,持续4周。
主要发现
- EV组双心室功能改善(左室P<0.0001;右室P=0.0037),左室扩张减少(P<0.0179)。
- EV组QRS时限缩短(P=0.0003),QTc间期缩短(P=0.0006)。
- EV组室性心律失常负荷(P=0.0042)和诱发性(P=0.0037)降低。
- 光学标测显示EV组复极加速(P=0.0290)和传导加快(P=0.0274)。
- EV治疗减少纤维化、细胞死亡,保留 connexin 43 表达,并降低炎症因子、NF-κB、NLRP3和CD68。
关键数值与推荐
- 体外和体内阻断EV hsa-miR-4488可重新激活NF-κB并削弱EV的有益效应。
临床怎么用
- EV可能作为ACM的潜在治疗策略,但尚未推荐用于人类。
- hsa-miR-4488-NF-κB轴可能是ACM抗炎抗心律失常治疗的候选靶点。
局限性
- 研究仅在小鼠模型中进行,需进一步研究才能转化至人类ACM。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Arrhythmogenic cardiomyopathy (ACM) is characterized by progressive loss of cardiomyocytes, and fibrofatty tissue replacement. Extracellular vesicles (EVs) secreted by cardiosphere-derived cells, immortalized, and engineered to express high levels of β-catenin, exert anti-inflammatory, and anti-fibrotic effects. The aim of the current study was to assess efficacy of EVs in an ACM murine model. METHODS AND RESULTS: Four-week-old homozygous knock-in mutant desmoglein-2 (Dsg2mt/mt) were randomized to receive weekly EVs or vehicle for 4 weeks. After 4 weeks, DSG2mt/mt mice receiving EVs showed improved biventricular function (left, P < 0.0001; right, P = 0.0037) and less left ventricular dilation (P < 0.0179). Electrocardiography revealed abbreviated QRS duration (P = 0.0003) and QTc interval (P = 0.0006) in EV-treated DSG2mt/mt mice. Further electrophysiology testing in the EV group showed decreased burden (P = 0.0042) and inducibility of ventricular arrhythmias (P = 0.0037). Optical mapping demonstrated accelerated repolarization (P = 0.0290) and faster conduction (P = 0.0274) in Dsg2mt/mt mice receiving EVs. DSG2mt/mt hearts exhibited reduced fibrosis, less cell death, and preserved connexin 43 expression after EV treatment. Hearts of Dsg2mt/mt mice expressed markedly increased levels of inflammatory cytokines that were, in part, attenuated by EV therapy. The pan-inflammatory transcription factor nuclear factor-κB (NF-κB), the inflammasome sensor NLRP3, and the macrophage marker CD68 were all reduced in EV-treated animals. Blocking EV hsa-miR-4488 in vitro and in vivo reactivates NF-κB and blunts the beneficial effects of EVs. CONCLUSIONS: Extracellular vesicle treatment improved cardiac function, reduced cardiac inflammation, and suppressed arrhythmogenesis in ACM. Further studies are needed prior to translating the present findings to human forms of this heterogenous disease.
引用
- Lin YN, Mesquita T, Sanchez L, et al. Extracellular vesicles from immortalized cardiosphere-derived cells attenuate arrhythmogenic cardiomyopathy in desmoglein-2 mutant mice. Eur Heart J. 2021. PMID: 34345905. doi:10.1093/eurheartj/ehab419
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。